According to Australian media outlet newsGP on July 5th, Philip Morris International (PMI) distributed marketing manuals to pharmacies in Australia. The manuals introduced the pricing of the e-cigarette product VEEV to customers. The manuals stated that VEEV can be used as a smoking cessation tool, and PMI will provide pharmacies that sign supply agreements with them with 80% of the total sales profit.
According to the report, the contact information for PMI can only be found in a small font single reference at the bottom of the manual.
The federal government has prohibited the importation of all non-prescription e-cigarettes and fully banned disposable e-cigarettes. E-cigarettes can only be purchased at pharmacies upon presentation of a prescription issued by a general practitioner.
According to the Royal Australian College of General Practitioners (RACGP) guidelines for smoking cessation, the use of e-cigarettes as a tool to quit smoking is considered a last-resort treatment method. Professor Nick Zwar, chair of the expert advisory group for the guidelines, stated that general practitioners need to be aware of the background of the prescription products they recommend. "I don't think many doctors would want to be associated with tobacco companies," said Prof. Zwar.
Nick Zwar questions whether large tobacco companies are qualified to provide prescription products for therapeutic purposes. He states, "They have always sought to sell nicotine-containing products, including combustible tobacco, to maximize profits, but at the expense of significant harm to human health and the economy." He believes that involving tobacco companies in products for therapeutic use poses a major conflict of interest.
Simon Chapman, a respected professor of public health at the University of Sydney, has claimed that Philip Morris International (PMI) has been actively promoting e-cigarettes as consumer products worldwide. Since the sale of e-cigarettes is currently only legal in Australia with a prescription, PMI is now attempting to exploit the law to gain an advantage by offering doctors 80% of the profits from e-cigarette sales. This move clearly shows their intention to outdo their competitors.
Simon Chapman believes that if PMI succeeds, the government's prescription plan is likely to fail, leading Australia to once again loosen restrictions on e-cigarette purchases, thus achieving the open consumer model desired by PMI.
When interviewed about the incident, the spokesperson of PMI stated that the company is making efforts to comply with the new laws.
A spokesperson from PMI stated that RACGP had participated in the development of the prescription e-cigarette guidelines, but they criticized PMI for being a responsible operator involved in it while ignoring the fact that many other companies are fueling the e-cigarette black market.
We urge the Royal Australian College of General Practitioners to collaborate with us in eliminating the black market of e-cigarettes and ensuring that individuals who choose to quit smoking using e-cigarettes have the option to use legitimate and regulated products such as VEEV after consulting with their general practitioners." the spokesperson said.
According to sources, PMI has engaged a company to distribute sales and marketing materials to pharmacies, and many pharmacies have already signed direct transaction agreements. The media reached out to these pharmacies for an interview but did not receive any response before the deadline.
Reference:
[1] Big Tobacco’s new push into pharmacy vapes
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
